logo
3 essential factors for investors to consider when aiming for passive income success

3 essential factors for investors to consider when aiming for passive income success

Yahoo09-02-2025

Seldom a week goes by without someone asking me how to earn passive income through investing. Since the rise of remote working during Covid, building wealth through passive income's become a key goal of many individuals.
The problem is that many wealth-building strategies aim to satiate the common desire for a rapid solution. When investing for income, the reality's usually a far cry from the get-rich-quick schemes touted by social media influencers.
If the thought of a long, drawn-out process is off-putting, consider this. When I started investing at 35, I thought I was too late. It took dedication but less than a decade later, I was well on my way towards earning a second income. If I'd hoped to see results within a year, I'd likely have given up.
Patience and dedication are key factors to consider, but they're not the only ones.
A key part of risk management is developing an appropriate asset allocation strategy. This essentially boils down to deciding how much risk is tolerable.
An investor who can survive on half their salary could potentially allocate the other 50% to investments. The decision then is how to divide that capital between bonds, commodities and stocks.
A 60/40 allocation (60% stocks, 40% bonds) is a popular option. Others may choose 30% commodities, 30% bonds and 40% stocks. Cash and bonds are considered low risk/low return, while stocks and commodities have higher risk/return potential.
An investor should always aim to achieve the perfect risk/reward balance based on their financial circumstances.
Picking the right stocks at the right time can make or break a portfolio. With the sheer amount of options available, it can be a daunting process. It may seem obvious to pick whatever big tech stocks are trending at the time but this method seldom works long term.
A truly diverse portfolio should also include some companies with a 20-30-year projection of stable growth. Think large, well-established and closely tied to the economic prosperity of the country. One example is Barclays (LSE: BARC).
Unlike HSBC, Barclays is more deeply rooted in the UK and less likely to move headquarters abroad. As the second-largest bank in the UK, it's very well-established and invested in the country's economic progress.
It's also been on a tear lately, with the price up 111% in the past year. Despite the rapid growth, it doesn't appear overvalued yet, with a forward price-to-earnings (P/E) ratio of only 7.3. This follows two years of slow growth during which high inflation subdued economic activity. With the first interest rate cut of 2025 done (and perhaps more on the horizon), the hope is that inflation will drop further this year.
Unfortunately, as a bank, it's highly sensitive to economic downturns — remember the 2008 financial crisis? Barclays crashed by over 80% during that period. There's always the risk that a similar event could send it tumbling again.
That's why diversity's key, not just between stocks but also between asset classes. Commodities tend to move inversely to stocks while bonds maintain stability in most situations.
I'm not looking to add more bank stocks to my portfolio right now but for investors aiming for long-term passive income, I think Barclays is a good option to consider.
The post 3 essential factors for investors to consider when aiming for passive income success appeared first on The Motley Fool UK.
More reading
5 Stocks For Trying To Build Wealth After 50
One Top Growth Stock from the Motley Fool
Mark Hartley has positions in HSBC Holdings. The Motley Fool UK has recommended Barclays Plc and HSBC Holdings. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
Motley Fool UK 2025

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

No Ad Comm ‘not necessarily positive' for Capricor, says Roth Capital
No Ad Comm ‘not necessarily positive' for Capricor, says Roth Capital

Yahoo

time39 minutes ago

  • Yahoo

No Ad Comm ‘not necessarily positive' for Capricor, says Roth Capital

Roth Capital analyst Boobalan Pachaiyappan tells investors in a research note that the FDA's intention not to require an Ad Comm 'at this time' for deramiocel for the treatment of cardiomyopathy associated with Duchenne Muscular Dystrophy 'may not necessarily be positive news,' and that it believes a promissory Ad Comm meeting would be positive, as a potential positive Ad Comm panel vote would put pressure on the new leadership to approve deramiocel in its current form. The firm reiterates a Buy rating and $31 price target on Capricor shares. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on CAPR: Disclaimer & DisclosureReport an Issue Capricor's deramiocel moves ahead without AdCom, says H.C. Wainwright HHS spokesperson tells Reuters FDA 'actively re-evaluating' Capricor AdCom Capricor Therapeutics provides regulatory update on Deramiocel BLA Roth says 'excessive' Capricor selloff due to 'investor overreaction' Capricor selloff brings buying opportunity, says H.C. Wainwright Sign in to access your portfolio

Building breakthroughs: Gilead invests in U.S. innovation
Building breakthroughs: Gilead invests in U.S. innovation

Axios

timean hour ago

  • Axios

Building breakthroughs: Gilead invests in U.S. innovation

Gilead's $32B U.S. investment is fueling American science — and innovation. At Gilead, we strive to create a healthier world for all people. Gilead invests in world-class science and is pursuing innovation across the therapeutic areas of virology, oncology and inflammation. Gilead is investing $32 billion in the U.S. through 2030 to expand research, manufacturing and workforce infrastructure as part of a broader global strategy to deliver scientific breakthroughs where they can have the greatest impact. The idea: Biopharmaceutical innovation can't happen without infrastructure. Gilead's expansion strategy helps ensure transformative medicines are discovered and delivered at home — while reinforcing the global pipeline that supports patients around the world. "Our U.S. investment strategy reflects a simple belief: that the future of medicine should be built here," said Daniel O'Day, Chairman and CEO of Gilead Sciences. "By strengthening our American footprint as part of a global innovation engine, we're helping ensure patients everywhere benefit from our world-class therapies." The strategy: Gilead's U.S. investment includes: Investing in AI-enabled labs and advanced manufacturing sites. Creating over 3,000 direct and supported jobs. Expanding capacity for personalized therapies and large-scale production. These efforts are designed to speed access to innovation, build supply chain resilience and redefine what's possible in medicine. Key numbers: 98% of Gilead's R&D infrastructure is U.S.-based. 80%+ of profits are reinvested in the U.S. $43B in projected U.S. economic impact. Investing in our promise Since 2017, Gilead has added more than 16,000 high-quality U.S. jobs, with over 70% of domestic employees focused on R&D. New investments are fueling advanced treatments in virology, inflammation and cancer. At Gilead, every investment begins with people and ends with purpose. Our commitment to expanding U.S. infrastructure goes beyond facilities — it's about empowering communities and strengthening public health for the long term. Engineering a new era of American innovation The details: Gilead is harnessing AI and automation to transform how medicines are discovered, manufactured, and delivered — faster, smarter and more safely. Next-generation facilities in California will be equipped with predictive analytics, digital monitoring and autonomous robotics. Designed in collaboration with Bay Area tech startups, these facilities set a new standard for biopharma infrastructure and speed — from groundbreaking to completion in under two years. With more than $5 billion invested in facilities that map the flow of scientific innovation — from research to clinical manufacturing — Gilead's campuses embody the speed and agility of our discoveries. Building resilience through science Plus, plus, plus: During COVID-19, Gilead's U.S.-anchored supply chain ensured uninterrupted global access to essential treatments. With the majority of our workforce and intellectual property based in the U.S. — and a global footprint spanning 70 sites across 38 countries — they're building a system that can adapt, shift and scale in real time. Strategic redundancy, flexible manufacturing and proven partnerships make our network a cornerstone of health security. A global commitment, rooted at home Worth a mention: While expanding its U.S. footprint, Gilead continues to invest in research, manufacturing and partnerships abroad. A globally integrated model ensures patients everywhere benefit from discoveries made at home. Whether scaling a COVID-19 antiviral across continents or sourcing ingredients for personalized therapies, Gilead's global operations balance efficiency with equity — and keep patients at the center of everything they do.

2 million student loan borrowers at risk of garnished wages: Analysis
2 million student loan borrowers at risk of garnished wages: Analysis

The Hill

timean hour ago

  • The Hill

2 million student loan borrowers at risk of garnished wages: Analysis

Nearly two million student loan borrowers are at risk of having their wages garnished this summer, according to a new estimate from TransUnion. Roughly six million federal student loan borrowers are newly delinquent — 90 days or more past due — and about a third could enter default as soon as next month, the credit-reporting agency said in an analysis Tuesday. By August, TransUnion estimates that an additional one million borrowers will be in default, at least 270 days behind on their payments. Once in default, borrowers could face a range of federal consequences, including docked pay, withheld tax refunds and reduced Social Security benefits. The renewed penalties follow the Trump administration's recent decision to lift a five-year pandemic-driven pause on involuntary collections, allowing the government to resume efforts to recover unpaid student loans. 'We continue to see more and more federal student loan borrowers being reported as the 90+ days delinquent, making a larger number of consumers vulnerable to entering default and the start of collections activities,' Michele Raneri, vice president and head of U.S. research and consulting at TransUnion, said in a statement. The share of federal student loan borrowers 90 days or more past due has climbed sharply from around 20 percent in February to 31 percent in April, the highest rate ever recorded, the company estimates. To put that in perspective: about 12 percent of student loan borrowers were 90 days or more past due in February 2020, before the COVID-19 pandemic. Delinquency comes before default and doesn't trigger wage garnishment on its own, but it can still hurt borrowers by lowering their credit scores. TransUnion's analysis found that newly delinquent borrowers have seen an average drop of 60 points. The report also included some cautiously optimistic findings, notably that the rate of delinquencies was nearly flat from March to April, suggesting they may have peaked. And although millions of borrowers could be just weeks away from defaulting, only 0.3 percent were in that status as of April, the company noted. Raneri urged borrowers who are at risk to contact their loan servicers as soon as possible to learn about potential options that may include income-driven repayment or other payment plans specific to their situation. In May, approximately 195,000 defaulted student loan borrowers began receiving official 30-day notices from the Treasury Department notifying them that their federal benefits could be withheld as early as June, according to the Education Department. The consequences of default can be severe, with the government able to garnish wages, potentially withholding up to 15 percent of a borrower's paycheck, among other penalties. The Trump administration ultimately paused a plan to garnish Social Security benefits, potentially sparing hundreds of thousands of older Americans from reduced retirement checks, at least for now. Overall, nearly 43 million borrowers owe more than $1.6 trillion in student debt, the Education Department said in April. Borrowers who have fallen behind can come up with a repayment strategy using the government's Loan Simulator tool here.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store